Loading page...
Loading page...
This round is closed. The next round and similar open calls are listed below. Synced from the EU Funding & Tenders Portal on 9 November 2026.
This call is closed. These open or upcoming calls fund the closest work.
Projects the EU funded under this call, with the organisation that led each one.
AIMARIAAccelerating Innovation in Marine AI-powered Bioprospecting
Led by Norges Teknisk-Naturvitenskapelige Universitet NTNU · Norway · 2026 · Official record ↗
OCEOMICSOCEAN COMPUTATIONAL EXPLORATION AND ANALYTICS FOR THE NOVEL BIOACTIVE MOLECULES’ DISCOVERY AND THEIR EXPLOITATION IN COSMETICS
Led by Ainia · Spain · 2026 · Official record ↗
Based on projects the EU funded on the same subject in this programme.
NEXTMARINENovel enzymes from extreme marine environments as a source for value-added targets
HORIZON-CL6-2024-CircBio-01-10 · 2025 · Official record ↗
CirculH2Hydrogenases for Large Scale Deployment of H2 as a Circular Energy Carrier in Industrial Biotechnology Based on Enzymatic Catalysts
HORIZON-CL6-2023-CircBio-01-5 · 2024 · Official record ↗
ROBUSTOORobust industrial biocatalysts with peroxygenase, phenol-oxidase or furfuryl-oxidase activities from bacterial and fungal hosts
HORIZON-CL6-2023-CircBio-01-5 · 2024 · Official record ↗
deCYPherDecipher cytochrome P450 enzymes (CYPs) by digital tools to produce flavonoids and terpenoids
HORIZON-CL6-2022-CIRCBIO-02-05-two-stage · 2023 · Official record ↗
NIAGARAUnderstanding, monitoring, and remediating the spread of chemical, microbiological and plastic pollution in drinking water treatment plants
HORIZON-CL6-2022-ZEROPOLLUTION-01-04 · 2023 · Official record ↗
XTREAMSustainable exploration and biodiscovery of novel products and processes from extreme aquatic microbiomes to expedite the circular bioeconomy
HORIZON-CL6-2024-CircBio-01-10 · 2025 · Official record ↗
NYMPHENew system-driven bioremediation of polluted habitats and environment
HORIZON-CL6-2021-ZEROPOLLUTION-01-10 · 2023 · Official record ↗
BLUETOOLSINNOVATIVE TOOLS FOR SUSTAINABLE EXPLORATION OF MARINE MICROBIOMINNOVATIVE TOOLS FOR SUSTAINABLE EXPLORATION OF MARINE MICROBIOMES: TOWARDS A CIRCULAR BLUE BIOECONOMY AND HEALTHIER MARINE ENVIRONMENTS
HORIZON-CL6-2022-CIRCBIO-01-07 · 2022 · Official record ↗
Each one links to its EU funding record and the partners it works with: a starting list for building a consortium.
Successful proposals should contribute to reaching the impacts of this destination, and European policies, in particular the European Green Deal, the bioeconomy strategy, the new approach for a blue economy. They should help harnessing the full potential of marine and freshwater biological resources and blue biotechnology is leveraged to deliver societal benefits, such as greener more environmentally friendly industrial products and processes, support public health and environmental conservation.
Project results are expected to contribute to all of the following expected outcomes:
The immense diversity of marine/aquatic micro- and macro-organisms and their communities represents a rich and largely unexplored reservoir of natural products and their base ingredients. To survive in habitats ranging from deep-sea sediments to polar regions or shallow waters, marine organisms have developed a broad spectrum of structures, defense mechanisms and metabolic pathways resulting in natural products with vast chemical diversity and wide range of biological activities. The biological interplay between interspecies communities, e.g. symbiotic or defence mechanisms, may offer attractive leads and is also in scope. For the coverage of terrestrial bioprospecting see parallel topic HORIZON-CL6-2025-01-CIRCBIO-08: Bioprospecting and optimized production of the terrestrial natural products: new opportunities for bio-based sectors.
The action covers modern biodiscovery approaches including, in-silico bioprospecting and the full integration of digital methods (e.g., statistics, algorithms, AI, data science, modelling, digital twins) with bioinformatics and biotechnological tools, which make possible the identification and production of bioactive natural compounds with potential high-value application in sectors such as pharmaceuticals, nutraceuticals, cosmetics, food/feed additives, agrochemicals, etc. In the context of this topic, natural products are understood as biologically active products such as secondary metabolites as well as enzymes derived from marine/aquatic organisms.
Targeted marine/aquatic biological resources can be sourced from their natural environment (in-situ) and/or from open access and public/private collections and gene-banks (ex-situ).
The aim is to broaden the range of novel compounds, lowering the production costs, quicken the development pipeline, and enable more innovation for the industrial operators, with clear-cut benefits for the final users. Projects should have a strong industry drive and include demonstration activities to proof the techno/economic viability of the production of the proposed marine/aquatic natural product(s) and/or the biodiscovery platform tools combining digital and biotechnologies.
The scope covers relevant steps of the biodiscovery process such as isolation and characterization of microbial strains and consortia, genomic characterisation, creation of natural product libraries, bioactivity screening, natural products isolation and purification, chemical structure elucidation or optimized production pathways via biotechnology and biomanufacturing approaches in suitable industrial facilities (bioreactors/biorefineries, e.g. for microbial production), synthetic biology or gene editing. The integration of digital approaches (AI, computer algorithms such as machine learning, modelling, data science etc) on optimizing the biodiscovery processes such as identification of biosynthetic gene clusters and metabolic pathways, enzyme selection, combinatorial assembly and annotation of high-throughput DNA sequencing data, bioactivity prediction, elucidation of the structure of compounds, experimental design etc is in scope. Safety to the end-users and operators needs to be assessed and guaranteed.
Proposals should avoid overlaps with past or ongoing topics (e.g. projects funded under the topic HORIZON-CL6-2022-CIRCBIO-02-05-two-stage: Life sciences and their convergence with digital technologies for prospecting, understanding and sustainably using biological resources, topic HORIZON-CL6-2023-CIRCBIO-01: Broadening the spectrum of robust enzymes and microbial hosts in industrial biotechnology), consider synergies to parallel actions (e.g. HORIZON-CL6-2025-01-CIRCBIO-08: Bioprospecting and optimized production of the terrestrial natural products: new opportunities for bio-based sectors as well as funded under the topic HORIZON-2020-FNR-11-2020 - Prospecting aquatic and terrestrial natural biological resources for biologically active compounds [1]). The action is expected to establish links with relevant projects funded under the EU Mission Restore our Ocean and Waters.
The action needs to guarantee biodiversity preservation. This can be addressed, inter alia, by covering propagation of biological material, including by in vitro cultivation, as well as by biotechnology approaches. The action needs to comply with applicable EU regulations and international rules on access to biological resources, their sustainable use and the fair and equitable sharing of benefits from their utilisation, including the Nagoya protocol, the Kunming-Montreal Global Biodiversity Framework (KM-GBF), and the agreement on the conservation and sustainable use of marine biological diversity of areas beyond national jurisdiction (BBNJ). A life-cycle assessment should be carried out to evaluate the environmental, economic, and social impact of the developed product(s). Proposals should contribute to the understanding of potential trade-offs inherent in the exploitation of ecosystems, their potential to deliver ecosystem services and ideally provide solution approaches to address these trade-offs. Potential risks to the environment, ecosystems, and society as well as benefits should also be assessed under this topic.
Proposals are encouraged to consider, where relevant, the services offered by European research infrastructures such as EU-OPENSCREEN, ELIXIR, EMBRC ERIC, IBISBA or other relevant research infrastructures138.
null
Activities are expected to achieve TRL 6-7 by the end of the project – see General Annex B. Activities may start at any TRL.
[1] https://cordis.europa.eu/programme/id/H2020_FNR-11-2020/en
1. Admissibility Conditions: Proposal page limit and layout
described in Annex A and Annex E of the Horizon Europe Work Programme General Annexes.
Proposal page limits and layout: described in Part B of the Application Form available in the Submission System.
2. Eligible Countries
described in Annex B of the Work Programme General Annexes.
A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon Europe projects. See the information in the Horizon Europe Programme Guide.
3. Other Eligible Conditions
described in Annex B of the Work Programme General Annexes.
4. Financial and operational capacity and exclusion
described in Annex C of the Work Programme General Annexes.
5a. Evaluation and award: Award criteria, scoring and thresholds
are described in Annex D of the Work Programme General Annexes.
5b. Evaluation and award: Submission and evaluation processes
are described in Annex F of the Work Programme General Annexes and the Online Manual.
5c. Evaluation and award: Indicative timeline for evaluation and grant agreement
described in Annex F of the Work Programme General Annexes.
6. Legal and financial set-up of the grants
described in Annex G of the Work Programme General Annexes.
described in the [specific topic of the Work Programme]
Application and evaluation forms and model grant agreement (MGA):
Application form templates — the application form specific to this call is available in the Submission System
Standard application form (HE RIA, IA)
Evaluation form templates — will be used with the necessary adaptations
Standard evaluation form (HE RIA, IA) 
Guidance
HE Programme Guide 
Model Grant Agreements (MGA)
HE MGA 
Call-specific instructions 
Additional documents:
HE Main Work Programme 2025 – 1. General Introduction
HE Main Work Programme 2025 – 9. Food, Bioeconomy, Natural Resources, Agriculture and Environment
HE Main Work Programme 2025 – 14. General Annexes
HE Programme Guide
HE Framework Programme 2021/695
HE Specific Programme Decision 2021/764 
EU Financial Regulation 2024/2509
Rules for Legal Entity Validation, LEAR Appointment and Financial Capacity Assessment 
EU Grants AGA — Annotated Model Grant Agreement 
Funding & Tenders Portal Online Manual 
Funding & Tenders Portal Terms and Conditions 
Funding & Tenders Portal Privacy Statement
Applicants asked the EU 2 questions about this call and the EU published the answers. They clarify the call documents but do not replace them.
As per the text describing the two topics, "HORIZON-CL6-2025-01-CIRCBIO-09: Bioprospecting and optimized production of the terrestrial natural products: new opportunities for bio-based sectors" and "HORIZON-CL6-2025-01-CIRCBIO-14 - Bioprospecting of marine natural products in the omics and artificial intelligence era", clinical trials are not a requested element and therefore should not be part of the proposal. What is indeed requested is that safety to the end-users and operators needs to be assessed and guaranteed. The required clinical trials for developing pharmaceuticals or their ingredients, should be planned outside of the project with other source of funding (for e.g. from Horizon Europe Health Cluster).
Read it on the EU portal ↗Answered 15 Jun 2025
It is the responsibility of the applicant to develop a suitable proposal. According to the topic text ‘Targeted marine/aquatic biological resources can be sourced from their natural environment (in-situ) and/or from open access and public/private collections and gene-banks (ex-situ)’. It is therefore not necessary that the proposal starts from TRL 1 – it could start at TRL 3-5. In fact, this is why prospecting could benefit from existing libraries and databases.
Please refer to the concrete definition of TRL 6 and 7, also found under Annex B of the Work Programme General Annexes:
TRL 6 — Technology demonstrated in relevant environment (industrially relevant environment in the case of key enabling technologies)
TRL 7 — System prototype demonstration in operational environment
To confirm clinical trials are not a required component of the proposal, and we reiterate that they should not be included. Additionally, we clarify that if a proposal involves the production of a pharmaceutical or its ingredient, the production process itself should achieve a TRL 6-7, whereas the demonstration of the pharmaceutical's efficacy is not expected to reach this level.
Read it on the EU portal ↗Answered 29 Aug 2025
Confirm the current call documents and submission conditions with the funding authority.
View on EU portal ↗Source: EU Funding & Tenders Portal · synced 2026-11-09
A free account keeps your shortlist and sends deadline reminders. The EUACC connector brings this call, its FAQs, past winners and similar calls into Claude or ChatGPT, so you can check fit and draft with sources.